Literature DB >> 25392361

Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.

Joshua R Stokell1, Raad Z Gharaibeh2, Timothy J Hamp3, Malcolm J Zapata3, Anthony A Fodor3, Todd R Steck4.   

Abstract

The evolution of pulmonary disease in cystic fibrosis (CF) usually begins when bacteria get trapped in mucus in the lungs and become established as a chronic infection. While most CF patients experience periods of stability, pulmonary exacerbations (PEs) can occur multiple times per year and result in permanent damage to the lungs. Little is known of the shift from a period of stability to a PE, but this shift is likely to be attributed to changes in the bacterial community. Here, we identified changes in the lung microbiota to determine if they reflect patient health, indicate the onset of exacerbations, or are related to antibiotic treatment. In contrast to most bacterial studies on CF, we collected weekly samples from an adult CF patient over a period of 3 years and performed quantitative PCR (qPCR) and Illumina sequencing on those samples. While many DNA-based studies have shown the CF microbiota to be relatively stable, we observed an increase in the total bacterial abundance over time (P < 0.001), while the number of different taxa (bacterial richness) and the number of different taxa and their abundances (diversity) significantly decreased over time (P < 0.03), which was likely due to repeated antibiotic exposure. Using genus-specific primers with qPCR, we observed an increase in the abundance of Burkholderia multivorans, a CF-associated pathogen, prior to the occurrence of a PE (P = 0.006). Combining these DNA-based techniques with frequent sampling identified a potential initiator for exacerbations and described a response of the CF microbiota to time and antibiotic treatment not observed in previous CF microbiota studies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25392361      PMCID: PMC4290929          DOI: 10.1128/JCM.02555-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!

Authors:  Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2004-04-01       Impact factor: 21.405

2.  UPARSE: highly accurate OTU sequences from microbial amplicon reads.

Authors:  Robert C Edgar
Journal:  Nat Methods       Date:  2013-08-18       Impact factor: 28.547

3.  Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?

Authors:  Franziska A Stressmann; Geraint B Rogers; Peter Marsh; Andrew K Lilley; Thomas W V Daniels; Mary P Carroll; Lucas R Hoffman; Graeme Jones; Collette E Allen; Nilesh Patel; Benjamin Forbes; Andrew Tuck; Kenneth D Bruce
Journal:  J Cyst Fibros       Date:  2011-06-12       Impact factor: 5.482

4.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

5.  Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis.

Authors:  T W V Daniels; G B Rogers; F A Stressmann; C J van der Gast; K D Bruce; G R Jones; G J Connett; J P Legg; M P Carroll
Journal:  J Cyst Fibros       Date:  2012-06-18       Impact factor: 5.482

Review 6.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

7.  Intestinal inflammation targets cancer-inducing activity of the microbiota.

Authors:  Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin
Journal:  Science       Date:  2012-08-16       Impact factor: 47.728

8.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

9.  Use of propidium monoazide for live/dead distinction in microbial ecology.

Authors:  Andreas Nocker; Priscilla Sossa-Fernandez; Mark D Burr; Anne K Camper
Journal:  Appl Environ Microbiol       Date:  2007-06-22       Impact factor: 4.792

10.  Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities.

Authors:  Christopher J van der Gast; Alan W Walker; Franziska A Stressmann; Geraint B Rogers; Paul Scott; Thomas W Daniels; Mary P Carroll; Julian Parkhill; Kenneth D Bruce
Journal:  ISME J       Date:  2010-12-09       Impact factor: 10.302

View more
  14 in total

Review 1.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

Review 2.  How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?

Authors:  Geraint B Rogers; Kenneth D Bruce; Lucas R Hoffman
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

3.  Episodic oral antibiotic use in CF: Discordance between the electronic medical record and self-report.

Authors:  Lindsay J Caverly; Tanner J Caverly; Linda M Kalikin; Bridget K Foster; Richard H Simon; John J LiPuma
Journal:  J Cyst Fibros       Date:  2016-05-05       Impact factor: 5.482

4.  Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens.

Authors:  Mona A Mahboubi; Lisa A Carmody; Bridget K Foster; Linda M Kalikin; Donald R VanDevanter; John J LiPuma
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

5.  Burkholderia multivorans Exhibits Antibiotic Collateral Sensitivity.

Authors:  Jerilyn Nicole Flanagan; Logan Kavanaugh; Todd R Steck
Journal:  Microb Drug Resist       Date:  2019-08-08       Impact factor: 3.431

Review 6.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 7.  Novel aspects of pathogenesis and regeneration mechanisms in COPD.

Authors:  Edvardas Bagdonas; Jovile Raudoniute; Ieva Bruzauskaite; Ruta Aldonyte
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-02

8.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

9.  Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung.

Authors:  Julio Diaz Caballero; Shawn T Clark; Bryan Coburn; Yu Zhang; Pauline W Wang; Sylva L Donaldson; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  MBio       Date:  2015-09-01       Impact factor: 7.867

10.  A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.

Authors:  Tessa M Andermann; Farnaz Fouladi; Fiona B Tamburini; Bita Sahaf; Ekaterina Tkachenko; Courtney Greene; Matthew T Buckley; Erin F Brooks; Haley Hedlin; Sally Arai; Crystal L Mackall; David Miklos; Robert S Negrin; Anthony A Fodor; Andrew R Rezvani; Ami S Bhatt
Journal:  Transplant Cell Ther       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.